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Objective:  This  study  aimed  to  prove  the  effect  of  Selenium  during  periconception  to  the  level
of Malodialdehyde  in  pregnancy.
Methods:  This  study  was  double  blind,  randomised,  control  community  based  trial  design.  The
intervention  group  (10  periconception  women)  received  Selenium  in  Multimicronutrient  (MMN),
while the  control  group  (22  periconception  women)  given  capsules  containing  Iron  and  Folic
Acid. During  preconceptional  period,  the  capsules  was  given  once  a  week,  while  in  pregnant
women was  once  a  day.  At  the  12th  and  20th  weeks  of  pregnancy,  selenium  and  MDA  were
measured.  Statistical  analysis  using  independent  T-test,  Paired  T-Test  and  PLS  analysis.
Results:  At  the  12th  weeks  of  pregnancy  the  level  of  MDA  in  Multimicronutrient  group  was
121.2 ng/mL  and  IFA  group  was  1436  ng/mL,  and  at  the  20th  weeks  in  MMN  group  was  108.4  ng/Ml
and IFA  group  was  199.6  ng/mL.  There  was  a  no  significant  difference  between  MDA  in  two
groups (p  =  0.424)  at  12th  week,  but  at  20th  weeks  MMN  group  had  a  significantly  lower  MDA
levels (p  =  0.006)  than  IFA  group.
Conclusion:  The  administration  of  selenium  in  MMN  preparations  since  the  preconception  period
has a  better  effect  in  reducing  MDA  levels  compared  to  the  IFA  group.
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Introduction
Preeclampsia  is  still  the  main  cause  of  mortility  and
morbidity  among  mothers  and  their  babies.  In  Indonesia,
preeclampsia  is  the  second  most  frequent  cause  of  mother
mortality.  About  16%  of  mother  mortality  cases  are  due  to
preeclampsia.1,2
The  mechanism  of  micro  nutrient  role  in  preventing
preeclampsia  has  not  been  completely  identified,  but  it  can
be  explained  through  antioxidant  and  oxidative  stress,  as
nutrition  can  balance  and  prevent  free  radicals  which  cause
oxidative  stress  during  pregnancy.3 Established  preeclamp-
sia  is  associated  with  increased  concentrations  of  oxidative
stress  markers  including  lipid  peroxidation  products,  and  a
reduction  in  antioxidant  concentrations.4
Efforts  to  prevent  preeclampsia  have  been  done  through
intervention  using  antioxidant  micronutrient,  because  there
is  an  evidence  of  the  involvement  of  placental  oxi-
dase.  Micronutrient  substances  are  strongly  correlated
with  complications  during  pregnancy  such  as  preeclampsia.
Oxidative  stress  plays  a  role  in  such  incidence.  In  some  jour-
nals,  it  is  claimed  that  the  intervention  is  not  effective,
and  there  is  even  a  potentiality  to  be  harmful.5,6 Therefore,
an  intervention  is  started  with  the  use  of  Selenium.  Sele-
nium  is  an  essential  micromineral  component  of  Glutathione
peroxidase  enzyme.  This  enzyme,  together  with  superoxide
dismutase  (SOD)  catalystand  vitamin  E  have  a  strong  antiox-
idant  power  to  survive  oxidative  damage  by  free  radicals.
Selenium  is  a  part  of  antioxidant  enzyme  that  protects  cells
and  lipid  membrane  from  oxidative  damage.7
The  role  of  Selenium  in  preventing  preeclampsia  has
been  proved  in  some  researches.8,9 It  is  evident  that  the
decrease  of  Selenium  level  results  in  oxidative  stress  in  the
placenta,  leading  to  preeclampsia  symptoms.10 The  rela-
tionship  between  Se  status  and  preeclampsia  incidence  is
shown  in  some  researches  in  45  countries.11 Se  supplemen-
tation  among  women  in  China  can  prevent  hypertension  and
oedema  during  pregnancy.12 An  interesting  study  on  animals
tries  to  show  that  diet  without  Se  results  in  some  symptoms
like  preeclampsia,  including  the  increase  of  blood  pressure,
proteinuria,  and  oxidative  stress  in  the  placenta  compared
to  the  use  of  normal  Se.13
The  role  of  selenium  intervention  in  preventing
preeclampsia  is  related  to  MDA  level.  A  review  conducted
by  Raijmakers  et  al.14 shows  that  Malondiadehyde  (MDA)  is
the  main  oxidative  stress  biomarker  found  in  the  circula-
tion  of  pre-eclampsia  women  where  a  number  of  studies
have  reported  that  this  lipid  peroxide  product  increases  in
preeclampsia  pregnancies.
A  1987  and  2005  review  and  a  recent  systematic  review  of
the  literature  between  1987  and  2007  concluded  that  overall
there  was  an  increase  in  MDA  in  women  with  preeclampsia.4
So  far,  research  on  selenium  supplementation  with  other
multimicronutrients  since  the  preconception  period  which
has  influenced  MDA  levels  in  pregnant  women  is  still  not
widely  practiced.  The  writers  have  not  found  any  research
on  selenium  intervention  with  Multiple  Micronutrient  prepa-
ration.  It  is  expected  that  the  combination  of  selenium  and
other  antioxidant  such  as  vitamin  A,  C,  and  E,  and  antioxi-
dant  minerals  such  as  ferrum,  zinc,  and  copper  can  provide
a  synergic  effect  against  free  radicals  and  prevent  placen-






revention  of  endothelium  tissue  that  can  increase  the  risk
f  molecular  preeclampsia.
It  is  then  necessary  to  conduct  a  research  about  the  effect
f  Selenium  intervention  in  (Multiple  Micronutrient/MMN)
reparation  since  preconception  period  on  the  levels  of
DA  to  prevent  oxidative  strees  in  pregnancy.  This  research
imed  to  analyse  the  level  of  MDA  before  and  after  the
dministration  of  Multimicronutrient  supplement  containing
elenium  and  to  compare  the  MDA  level  at  the  12th  and  20th
eeks  of  pregnancy  in  the  intervention  and  control  groups.
ethods
esign
he  research  will  be  conducted  in  three  subdistricts  in
anggai  regency.  These  three  subdistricts  are  selected  pur-
osively  as  the  representation  of  Banggai  regency  area  based
n  some  considerations.  First,  the  rate  of  preeclampsia  is
igh  in  these  three  areas.  Second,  the  three  locations  are
ccessible,  making  it  possible  for  monitoring  and  controlling
he  intervention.  Third,  the  three  subdistricts  are  similar  in
erms  of  the  socioeconomic  aspect.  Finally,  people  mobility
n  the  three  subdistricts  is  relatively  low.
This  study  can  be  considered  a  true  experimental
esearch  using  the  double  blind  community-based  trial
esign.  It  can  also  be  regarded  as  an  efficacy  study  aimed  to
nalyse  the  advantage  or  benefit  of  an  intervention  under  a
ight  control.15 The  scheme  description  is  as  follows:
opulation  and  study  setting
he  number  of  samples  is  determined  with  a  90%  power
o  detect  386  differences  of  sFlt-1  concentration,  with
ype  I  error  in  ˛  =  0.05  on  one  side,  standard  deviation
SD)  772  (based  on  the  study  of  Mousavi  M.16 There  are
4  preconcentional  mothers  in  each  group.  The  research
opulation  includes  preconceptional  mothers  who  register
n  the  programme  of  Praconception  Integrated  Service  Cen-
re.  They  are  from  three  subdistricts  in  Banggai  regency.
he  samples  are  eligible  respondents  based  on  some  inclu-
ion  criteria:  praconceptional  mothers,  do  not  have  previous
regnancy,  married,  aged  18--35  years  old,  plan  to  be
regnant  in  less  than  one  year,  and  agree  to  partici-
ate  in  the  research  by  signing  an  informed  consent.  The
xclusion  criteria  are  preconceptional  mothers  with  hyper-
lycemia,  ddabetes  mellitus,  kidney  failure,  hypertension,
nd  tuberculosis;  not  a  permanent  citizen  in  the  areas  (stay
uration  <  6  months),  not  living  with  husband,  twin  preg-
ancy,  obesity  (IMT  >  30),  severe  anaemia  (<7  g/l),  upper
rm  circumference  < 23.5  cm,  positive  proteinuria  (++),  six-
onth  participation  in  the  intervention  programme  but  not
etting  pregnant,  have  been  married  >  6  years  but  never  get
regnant.
A  block  IV  randomisation  results  in  a  group  receiving  sele-
ium  and  Multimicronutrient,  and  a  control  group  receiving
rogramme  capsules  containing  Iron  and  Folic  Acid.  The
MN  capsules  containing  Selenium  and  other  Multimicronu-
rient  will  be  given  once  a  week  when  the  mothers  are  not
regnant,  and  once  a  day  during  pregnancy.  The  interven-
ion  will  be  stopped  when  after  six-month  intervention,  the
116  Y.  Monoarfa  et  al.
Table  1  The  composition  of  iron  folic  acid  and  multiple  micronutrient  supplements.
Ingredient  Preconception  (weekly)  RDA  for  non-pregnant  women
IFA  MMN
Vitamin  A,  RE  800  700
Vitamin B12,  g  2.6  2.4
Vitamin B6,  mg  1.9  1.3
Riboflavin (B2),  mg 1.4 15
Vitamin  C,  mg 70  75
Vitamin D,  IU 10  15
Vitamin E,  mg  10  15
Zinc, mg  15  8
Iron, mg  600  30  18
Niacin, mg  18  14
Selenium g  65  55
Copper, mg  2  900  mcg/day























Iodine, g  15
others  do  not  get  pregnant  so  that  the  respondents  will  be
onsidered  dropped  out  (Table  1).
The  distribution  of  intervention  and  control  capsules  to
others  will  be  conducted  starting  from  the  researcher  to
ubdistrict  coordinators,  who  will  then  distribute  the  cap-
ules  to  village  midwives.  These  village  health  workers  will
istribute  the  capsules  among  the  cadres  of  integrated  ser-
ice  centres  in  each  village.  Respondents  will  be  visited  once
n  a  week  to  distribute  the  MMN  capsules  as  well  as  to  control
he  adherence  in  consuming  the  MMN  capsules.  During  the
esearch,  the  mothers  will  not  be  allowed  to  consume  vita-
in  and  minerals  from  other  sources.  Any  violation  of  this
equirement  will  result  in  the  cancellation  of  respondents’





Table  2  Data  collection  and  measurements.
Measurements  Precon






Exposure  to  pollutans
√








Food recall  24  h
√  




















ypes  and  time  of  data  collection  can  be  seen  in  Table  2.
Pregnant  mothers  will  be  required  to  consume  one  sup-
lement  capsule  before  night  sleeping  every  day.  The  cadre
ill  distribute  the  supplements  every  fortnight,  and  at  the
ame  time,  the  cadre  will  monitor  the  consumption.  In  addi-
ion,  the  cadre  will  also  record  side  effects  and  any  pain  felt
y  the  mothers.  Furthermore,  the  pregnant  mothers  will
ave  blood  pressure  examination,  proteinuria  assessment,
nd  anthropometric  measurement.  Their  blood  samples  will
lso  be  taken  to  determine  the  levels  of  hb,  glucose,  and
DA  at  the  first  stage.  At  the  12th  and  20th  weeks  of
regnancy,  blood  sample  examination  will  be  conducted  to
ception  Pregnancy


























Effect  of  selenium  during  periconception  period  on  the  leve
measure  MDA  level  at  the  second  stage.  The  pregnant  moth-
ers  will  also  have  blood  pressure  measurement  every  month,
and  proteinuria  examination  at  the  20th  week  of  pregnancy.
After  the  samples  are  taken  for  examination,  the  admin-
istration  of  Multiple  Micronutrient  will  be  continued  until
the  time  close  to  baby  delivery.  The  examination  of  MDA
level  will  be  conducted  in  the  Clinical  Pathology  Laboratory
of  Dr.  Soetomo  hospital.  The  pregnancy  examination  will
be  conducted  by  village  midwives  at  the  Intergated  Service
Centre  or  Village  Health  Centre.  Pregnant  mothers  experi-
encing  complications  will  be  referred  to  an  Obstetrics  and
Gynecology  specialist.Result
The  results  of  laboratory  analysis  showed  the  average  value
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Figure  2  Comparison  of  mean  values  of  MDA  in  preconceptions,  wealondialdehyde  117
t  12  weeks  as  shown  in  Fig.  1. In  the  MMN  group,  the
ean  sect  of  MDA  at  preconception  time  was  112.8  ng/mL
lightly  lower  than  Iron  Folit  Acid  group  of  120.8  ng/mL.
urthermore,  at  12  weeks  of  gestation  the  mean  score  of
DA  in  the  MMN  group  increased  to  121.2  ng/mL  (p  =  0.681)
o  in  the  Iron  Folit  Acid  group  increased  to  143.6  ng/mL
p  =  0.636).  The  mean  value  of  the  MDA  was  then  decreased
o  108.4  ng/mL  in  MMN  group  at  20th  week  of  pregnancy,
nd  the  Folate  Iron  group  increased  to  199.6  ng/mL.
Fig.  2  shows  that  at  week  12  there  was  an  increase  of  MDA
n  both  groups,  i.e.  8.4  points  in  MMN  group  and  22.8  points
n  Iron  Folit  Acid  group.  Furthermore,  at  week  12--20th  week
f  pregnancy,  in  MMN  group  there  was  a decrease  of  MDA  of
2.8  points  (p  =  0.636),  and  in  Iron  Folit  Acid  group  there  was
n  increase  of  MDA  by  56  points  (p  =  0.030).  Thus,  a  greater
ecrease  in  MDA  occurred  in  the  MMN  group  than  in  the
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16. De Lucca L, Gallarreta FM, de Lima Gonçalves T. Oxidative stress
markers in pregnant women with preeclampsia. Am J Med Biol
Res. 2015;3:68--73.18  
The  statistical  analysis  showed  that  the  mean  difference
f  the  mean  MDA  for  the  two  groups  at  week  12  was  −22.38
ith  p  value  =  0.424,  whereas  at  week  20,  the  mean  dif-
erence  was  −91.3  p  value  (0.006).  There  were  significant
ifferences  in  either  group  at  week  20.
iscussion
he  results  of  the  study  in  Fig.  2  show  that  at  12  weeks
f  gestation  an  increase  in  the  MDA  in  both  groups  was
21.2  ng/mL  respectively  in  the  MMN  group  and  143.6  ng/mL
n  the  Folate  Iron  group.  In  both  groups  there  was  no  signif-
cant  difference  with  the  value  of  p  =  0.424.
The  increase  in  MDA  levels  in  this  study  is  in  line  with  the
esults  of  Lucca  L’s  study16 which  showed  that  in  pregnancy
here  was  an  increase  in  MDA  levels,  despite  the  inter-
ention  of  antioxidant  supplements  since  the  beginning  of
regnancy.  This  condition  is  associated  with  high  metabolic
eeds  and  increased  oxygen  demand  in  the  tissues  resulting
n  increased  production  of  reactive  oxygen  species.16 Thus
he  efficacy  of  selenium  supplementation  in  MMN  prepara-
ion  given  since  preconception  has  a  better  effect  than  the
ron  Folate  group  in  suppressing  the  rate  increase  of  MDA
evels  at  week  12  of  pregnancy.
Furthermore,  at  20th  week  of  gestation  the  decrease  in
DA  level  occurred  in  MMN  group,  i.e.  108.4  ng/mL  in  the
MN  group  and  on  the  other  hand,  in  the  Iron  Folate  group
here  was  an  increase  in  MDA  levels  (199.6  ng/mL).  In  the
0th  week  of  pregnancy  there  was  significant  difference
etween  the  two  groups  with  p  =  0.006.
onclusion
hus,  it  can  be  concluded  that  the  efficacy  of  selenium
upplementation  in  MMN  preparations  given  since  precon-
eption  time  is  more  effective  in  reducing  the  MDA  level  at
0  weeks  of  pregnancy  than  in  the  group  given  the  Iron  Folit
cid  supplement.  This  condition  is  very  good  in  preventing
xidative  stress  in  pregnancy  and  preeclampsia  early.
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